IP Library Granted Patent US 7,700,368
Granted Patent B2
US 7,700,368 · App. 10/528,951 · Granted Apr 20, 2010

Methods of purifying cannabinoids from plant material

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,368
App. No.
10/528,951
Granted
Apr 20, 2010
Kind
B2
Abstract

The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.

Claims (9)

1. A method for producing Δ 9 tetrahydrocannabivarin (Δ 9 THCV) crystals comprising:

i) obtaining an ethanolic solution of a botanical drug substance from cannabis plant material,

ii) passing the solution obtained in step i) through a column of activated charcoal, and collecting the eluate,

iii) remove solvent from the eluate by rotary evaporation to give a Δ 9 THCV enriched fraction,

iv) passing a solution of the resulting Δ 9 THCV enriched extract through a column packed with Sephadex LH20, eluting with 2:1 chloroform/dichloromethane,

v) collecting Δ 9 THCV rich fractions and removing solvent by rotary evaporation,

vi) re-dissolving the crude Δ 9 THCV prepared in step v) in methanol, removing insoluble residue by filtration and removing solvent from the filtrate by rotary evaporation, and

vii) re-dissolving the crude Δ 9 THCV prepared in step vi) in pentane, removing insoluble residue by filtration and removing solvent from the filtrate by rotary evaporation to give said crystals of Δ 9 THCV.

2. A substantially pure preparation of Δ 9 tetrahydrocannabivarin (Δ 9 THCV) obtained by the method of claim 1 , having a chromatographic purity of greater than 95%, more preferably greater than 96%, more preferably greater than 97%, more preferably greater than 98%, and most preferably greater than 99% by area normalisation of an HPLC profile.

Assignments (3)
CHANGE OF NAME Recorded May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071097/0088 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2010
From: FLOCKHART, IAN R.; WHEATLEY, GARY WILLIAM; DRING, SU; ARCHER, LESLIE
To: GW PHARMA LIMITED
Reel/Frame 024594/0442 →